UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
 
(Amendment No. 6)*
 
Agios Pharmaceuticals, Inc.
(Name of Issuer)
 
Common Stock, $0.001 par value
(Title of Class of Securities)
 
00847X104
(CUSIP Number)

Sandra Leung, Esq.
Bristol-Myers Squibb Company
430 East 29th Street, 14th Floor
New York, New York 10016
(212) 546-3309

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
 
April 5, 2021
(Date of Event Which Requires Filing of This Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box: ☐
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
 
*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.	
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00847X104

1	NAMES OF REPORTING PERSONS	 	 	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

BRISTOL-MYERS SQUIBB COMPANY
22-0790350	 	 	
		 	 	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	☐	
	 	(b)	☐	
		 	 	
3	SEC USE ONLY	 	 	

4	SOURCE OF FUNDS (SEE INSTRUCTIONS)	 	 	
	OO	 	 	
		 	 	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)	 	☐	

6	CITIZENSHIP OR PLACE OF ORGANIZATION	 	 	
	Delaware, U.S.A.	 	 	
		 	 	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER	 	 	
		0	 	 	
			 	 	
	8	SHARED VOTING POWER	 	 	
		0	 	 	
			 	 	
	9	SOLE DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
	10	SHARED DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	 	
	0	 	 	
		 	 	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	 	☐	

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	 	 	
	0	 	 	
		 	 	
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)	 	 	
	CO	 	 	

CUSIP No. 00847X104

1	NAMES OF REPORTING PERSONS	 	 	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

CELGENE CORPORATION
22-2711928	 	 	
		 	 	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	☐	
	 	(b)	☐	
		 	 	
3	SEC USE ONLY	 	 	

4	SOURCE OF FUNDS (SEE INSTRUCTIONS)	 	 	
	OO	 	 	
		 	 	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)	 	☐	

6	CITIZENSHIP OR PLACE OF ORGANIZATION	 	 	
	Delaware, U.S.A.	 	 	
		 	 	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER	 	 	
		0	 	 	
			 	 	
	8	SHARED VOTING POWER	 	 	
		0	 	 	
			 	 	
	9	SOLE DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
	10	SHARED DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	 	
	0	 	 	
		 	 	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	 	☐	

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	 	 	
	0	 	 	
		 	 	
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)	 	 	
	CO	 	 	

CUSIP No. 00847X104

1	NAMES OF REPORTING PERSONS	 	 	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

CELGENE SWITZERLAND LLC
47-5587373	 	 	
		 	 	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	☐	
	 	(b)	☐	
		 	 	
3	SEC USE ONLY	 	 	

4	SOURCE OF FUNDS (SEE INSTRUCTIONS)	 	 	
	OO	 	 	
		 	 	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)	 	☐	

6	CITIZENSHIP OR PLACE OF ORGANIZATION	 	 	
	Delaware, U.S.A.	 	 	
		 	 	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER	 	 	
		0	 	 	
			 	 	
	8	SHARED VOTING POWER	 	 	
		0	 	 	
			 	 	
	9	SOLE DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
	10	SHARED DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	 	
	0	 	 	
		 	 	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	 	☐	

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	 	 	
	0	 	 	
		 	 	
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)	 	 	
	OO (limited liability company)	 	 	

CUSIP No. 00847X104

1	NAMES OF REPORTING PERSONS	 	 	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

CELGENE EUROPEAN INVESTMENT COMPANY LLC
90-0587060	 	 	
		 	 	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	☐	
	 	(b)	☐	
		 	 	
3	SEC USE ONLY	 	 	

4	SOURCE OF FUNDS (SEE INSTRUCTIONS)	 	 	
	OO	 	 	
		 	 	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)	 	☐	

6	CITIZENSHIP OR PLACE OF ORGANIZATION	 	 	
	Delaware, U.S.A.	 	 	
		 	 	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER	 	 	
		0	 	 	
			 	 	
	8	SHARED VOTING POWER	 	 	
		0	 	 	
			 	 	
	9	SOLE DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
	10	SHARED DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	 	
	0	 	 	
		 	 	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	 	☐	

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	 	 	
	0	 	 	
		 	 	
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)	 	 	
	OO (limited liability company)	 	 	

CUSIP No. 00847X104

1	NAMES OF REPORTING PERSONS	 	 	
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

CELGENE ALPINE INVESTMENT CO., LLC
45-4054818	 	 	
		 	 	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a)	☐	
	 	(b)	☐	
		 	 	
3	SEC USE ONLY	 	 	

4	SOURCE OF FUNDS (SEE INSTRUCTIONS)	 	 	
	OO	 	 	
		 	 	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)	 	☐	

6	CITIZENSHIP OR PLACE OF ORGANIZATION	 	 	
	Delaware, U.S.A.	 	 	
		 	 	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER	 	 	
		0	 	 	
			 	 	
	8	SHARED VOTING POWER	 	 	
		0	 	 	
			 	 	
	9	SOLE DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
	10	SHARED DISPOSITIVE POWER	 	 	
		0	 	 	
			 	 	
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	 	 	
	0	 	 	
		 	 	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	 	☐	

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	 	 	
	0	 	 	
		 	 	
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)	 	 	
	OO (limited liability company)	 	 	

This Amendment No. 6 is being filed by Bristol-Myers Squibb Company, a Delaware corporation (“BMS”), Celgene Corporation, a Delaware corporation (“Celgene”), which is a direct wholly owned subsidiary of BMS, Celgene Switzerland, LLC, a Delaware limited liability company (“Celgene Switzerland”), which is an indirect subsidiary of Celgene, Celgene European Investment Company, LLC, a Delaware limited liability company (“CEIC”), which is an indirect subsidiary of Celgene, and Celgene Alpine Investment Co., LLC, a Delaware limited liability company (“CAIC,” and together with BMS, Celgene, Celgene Switzerland, and CEIC, the “Reporting Persons”), which is an indirect subsidiary of Celgene, with respect to common stock, par value $0.001 per share (“Common Stock”), of Agios Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and amends the Schedule 13D (the “Schedule 13D”) filed with the Securities and Exchange Commission (the “Commission”) by CEIC on August 6, 2013, as amended by Amendment No. 1 filed with the Commission by CEIC on April 30, 2014, Amendment No. 2 filed with the Commission by CEIC on December 17, 2014, Amendment No. 3 filed with the Commission by CEIC on April 24, 2017, Amendment No. 4 filed with the Commission by CEIC on January 23, 2018, and Amendment No. 5 filed with the Commission by CEIC on November 12, 2019. BMS is the ultimate parent company of Celgene, Celgene Switzerland, CEIC, and CAIC. Capitalized terms used, but not defined herein, have the meanings ascribed to them in the Schedule 13D.
 
On November 20, 2019 (the “Closing Date”), BMS completed its acquisition of Celgene pursuant to the terms and conditions of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 2, 2019, by and among BMS, Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (“Merger Sub”), and Celgene. Under the Merger Agreement, on the Closing Date, Merger Sub merged with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS (the “Merger”).
 
Item 1.	Security and Issuer.	
 
No modification.
 
Item 2.	Identity and Background.	
 
Item 2 is hereby amended and supplemented as follows:
 
On the Closing Date, BMS completed its acquisition of Celgene pursuant to the terms and conditions of the Merger Agreement, dated as of January 2, 2019, by and among BMS, Merger Sub and Celgene. Under the Merger Agreement, on the Closing Date, Merger Sub merged with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS.
 
This statement is being filed to add BMS as a Reporting Person. The Reporting Persons are filing jointly, and the agreement among the Reporting Persons to file jointly is attached hereto as Exhibit No. 99.1 and is incorporated herein by reference.
 
Each of BMS and Celgene is a Delaware corporation.
 
Each of Celgene Switzerland, CEIC, and CAIC is a Delaware limited liability company.
 
The principal business address of BMS is 430 E. 29th Street, 14th Floor, New York, NY 10016. BMS is a global biopharmaceutical company primarily engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.
 
The principal business address of Celgene is 86 Morris Avenue, Summit, NJ 07901. Celgene is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
 
The principal business address of Celgene Switzerland is AON House, 30 Woodbourne Avenue, Pembroke, HM 08, Bermuda. Celgene Switzerland is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

The principal business address of CEIC is AON House, 30 Woodbourne Avenue, Pembroke, HM 08, Bermuda . CEIC is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
 
The principal business address of CAIC is AON House, 30 Woodbourne Avenue, Pembroke, HM 08, Bermuda . CAIC is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
 
Set forth on Schedule A hereto, which is incorporated herein by reference, is the name, business address, principal occupation or employment and the name, principal business and citizenship of each of the directors and executive officers of the Reporting Persons.
 
During the past five years, none of the Reporting Persons or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto, has been (i) convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors), or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
 
Item 3.	Source and Amount of Funds or Other Consideration.	
 
Item 3 is hereby amended and supplemented as follows:
 
As described above, on the Closing Date, BMS and Celgene completed the Merger. Under the Merger Agreement, on the Closing Date, Merger Sub merged with and into Celgene with Celgene surviving as a direct wholly owned subsidiary of BMS.
 
The disclosure in Item 5 of this Amendment No. 6 is incorporated by reference into this Item 3.
 
Item 4.	Purpose of Transaction.	
 
Item 4 is hereby amended and supplemented by adding the following:
 
As described above, on the Closing Date, BMS and Celgene consummated the Merger, as a result of which BMS became the ultimate beneficial owner of the Common Stock of the Issuer.
 
The disclosure in Item 5 of this Amendment No. 6 is incorporated by reference into this Item 4.
 
Item 5.	Interest in Securities of the Issuer.	
 
Items 5(a)-(c) is hereby amended and supplemented as follows:
 
On March 31, 2021, BMS entered into a definitive agreement with the Issuer in which Celgene, Celgene Switzerland, CEIC, and CAIC agreed to sell a total of 7,121,658 shares of Common Stock of the Issuer in a private sale pursuant to Rule 144 under the Securities Act of 1933, as amended, at an aggregate purchase price of $48.3785 per share, resulting in aggregate proceeds of approximately $344.5 million in cash (the “Sale”). As a result of the close of the Sale on April 5, 2021, the Reporting Persons ceased to beneficially own more than five percent of the Issuer’s Common Stock and therefore are no longer subject to the beneficial ownership reporting provisions of Section 13(d) of the Securities Exchange Act of 1934, as amended.
 
Item 5(e) is hereby amended and supplemented as follows:
 
As of April 5, 2021, the Reporting Persons ceased to beneficially own more than five percent of the Issuer’s Common Stock.

Item 6.	Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.	
 
Item 6 is hereby amended and supplemented as follows:
 
The information set forth in Item 5 of this Amendment No. 6 is hereby incorporated by reference into this Item 6.
 
Item 7.	Material to Be Filed as Exhibits.	
 
Item 7 of the Schedule 13D is hereby amended and supplemented by adding the following document as an exhibit:

Exhibit Description

99.1	Joint Filing Agreement, dated April 5, 2021, between BMS, Celgene, Celgene Switzerland, CEIC, and CAIC.	

SIGNATURE
 
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
 
Dated:  April 5, 2021	BRISTOL-MYERS SQUIBB COMPANY	
 	 	
 	By:	/s/ Katherine R. Kelly	
 		Name:	Katherine R. Kelly	
 		Title:	Corporate Secretary	

 	CELGENE CORPORATION	
 	 	
 	By:	/s/ Phil M. Holzer	
 		Name:	Phil M. Holzer	
 		Title:	President	

 	CELGENE SWITZERLAND LLC	
 	 	
 	By:	/s/ Kevin Mello	
 		Name:	Kevin Mello	
 		Title:	Manager	

 	CELGENE EUROPEAN INVESTMENT COMPANY	
 	 	
 	By:	/s/ Kevin Mello	
 		Name:	Kevin Mello	
 		Title:	Manager	

 	CELGENE ALPINE INVESTMENT CO., LLC	
 	 	
 	By:	/s/ Kevin Mello	
 		Name:	Kevin Mello	
 		Title:	Manager	

SCHEDULE A
 
Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of the Reporting Persons
 
The name, business address and present principal occupation or employment of each of the directors and executive officers of the Reporting Persons are set forth below. The business address of each director and executive officer of BMS is c/o 430 E. 29th Street, 14th Floor, New York, NY 10016. The business address of each director and executive officer of Celgene is c/o 86 Morris Avenue, Summit, New Jersey 07901. Unless otherwise indicated, each director and executive officer is a citizen of the United States.
 
BRISTOL-MYERS SQUIBB COMPANY - BOARD OF DIRECTORS
 
Name and Position	 	Present Principal Occupation or Employment	
 	 	 	
Giovanni Caforio, M.D.*
Chief Executive Officer
Chairman of the Board of Directors	 	Chief Executive Officer and Chairman of the Board of Directors of Bristol-Myers Squibb Company	
 	 	 	
Peter J. Arduini
Director	 	President and Chief Executive Officer of Integra LifeSciences Holdings Corporation	
 	 	 	
Robert Bertolini
Director	 	Former President and Chief Financial Officer of Bausch & Lomb Incorporated	
 	 	 	
Michael W. Bonney
Director	 	Chair of the Board of Kaleido Biosciences, Inc.	
 	 	 	
Matthew W. Emmens
Director	 	Retired Chief Executive Officer and Chairman of the Board of Shire PLC	
 	 	 	
Julia A. Haller, M.D.
Director	 	Ophthalmologist-in-Chief of the Wills Eye Hospital, Philadelphia, PA	
 	 	 	
Dinesh C. Paliwal
Director	 	Retired Chairman and Chief Executive Officer of Harman International	
 	 	 	
Paula A. Price
Director	 	Former Executive Vice President and Chief Financial Officer of Macy’s, Inc.	
 	 	 	
Derica W. Rice
Director	 	Former Executive Vice President of CVS Health and President, Pharmacy Benefits Business of CVS Caremark	
 	 	 	
Theodore R. Samuels
Director	 	Retired President of Capital Guardian Trust Company	
 	 	 	
Vicki L. Sato, Ph.D.
Lead Independent Director	 	Chairman of the Board of Denali Therapeutics, Inc.	
 	 	 	
Gerald L. Storch
Director	 	Chief Executive Officer of Storch Advisors	
 	 	 	
Karen H. Vousden, Ph.D.**
Director	 	Senior Group Leader, The Francis Crick Institute and Chief Scientist,
Cancer Research UK	
 	 	 	
Phyllis R. Yale
Director	 	Advisory Partner, Bain & Company	

A-1

BRISTOL-MYERS SQUIBB COMPANY - EXECUTIVE OFFICERS
 
Name	 	Title	
Giovanni Caforio, M.D.*	 	Chairman of the Board and Chief Executive Officer	
Christopher Boerner, Ph.D.	 	Executive Vice President and Chief Commercialization Officer	
Adam Dubow	 	Senior Vice President, Chief Compliance and Ethics Officer	
Joseph E. Eid, M.D.	 	Senior Vice President and Head of Global Medical Affairs	
David V. Elkins	 	Executive Vice President and Chief Financial Officer	
Samit Hirawat, M.D.	 	Executive Vice President, Chief Medical Officer, Global Drug Development	
Sandra Leung	 	Executive Vice President and General Counsel	
Elizabeth A. Mily	 	Executive Vice President, Strategy & Business Development	
Ann M. Powell	 	Executive Vice President, Chief Human Resources Officer	
Lou Schmukler	 	Executive Vice President and President, Global Product Development & Supply	
Catalina Vargas	 	Chief of Staff to the Chief Executive Officer	
Rupert Vessey, D.Phil.	 	Executive Vice President and President, Research and Early Development	
Paul von Autenried	 	Executive Vice President, Chief Information Officer	

*Citizen of the United States and Italy
**Citizen of the United Kingdom

CELGENE CORPORATION - BOARD OF DIRECTORS
 
Name and Position	 	Present Principal Occupation or Employment	
Phil M. Holzer
Director	 	Senior Vice President, Head of Enterprise Integration Management Office, Bristol-Myers Squibb Company	
 	 	 	
Katherine R. Kelly
Director	 	Vice President and Corporate Secretary, Bristol-Myers Squibb Company	

CELGENE CORPORATION - EXECUTIVE OFFICERS
 
Name	 	Title	
Phil M. Holzer	 	President	
Jeffrey Galik	 	Vice President and Treasurer	
Katherine R. Kelly	 	Vice President and Secretary	
Lisa Goldey	 	Vice President	
Sophia Park	 	Vice President	
Elisabeth S. Bradley	 	Assistant Secretary	

CELGENE SWITZERLAND, LLC
 
Name and Position	 	Present Principal Occupation or Employment	
Kevin Mello, Manager	 	Associate Director, Banking Operations, Bristol-Myers Squibb Company	

CELGENE EUROPEAN INVESTMENT COMPANY, LLC
 
Name and Position	 	Present Principal Occupation or Employment	
Kevin Mello, Manager	 	Associate Director, Banking Operations, Bristol-Myers Squibb Company	

CELGENE ALPINE INVESTMENT CO., LLC
 
Name and Position	 	Present Principal Occupation or Employment	
Kevin Mello, Manager	 	Associate Director, Banking Operations, Bristol-Myers Squibb Company	

A-2

Exhibit 99.1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with the other Reporting Person (as such term is defined in the Schedule 13D/A referred to below) on behalf of each of them of a statement on Schedule 13D (including any and all amendments thereto) with respect to Common Stock, par value $0.001 per share, of Agios Pharmaceuticals, Inc., a Delaware corporation, and that this Agreement may be included as an Exhibit to such joint filing.
 
The undersigned further agree that each party hereto is responsible for the timely filing of such Statement on Schedule 13D and any amendments thereto, and for the accuracy and completeness of the information concerning such party contained therein, provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate.
 
This Agreement may be executed in any number of counterparts, all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this fifth day of April, 2021.

	BRISTOL-MYERS SQUIBB COMPANY	
 	 	
 	By:	/s/ Katherine R. Kelly	
 		Name:	Katherine R. Kelly	
 		Title:	Corporate Secretary	

 	CELGENE CORPORATION	
 	 	
 	By:	/s/ Phil M. Holzer	
 		Name:	Phil M. Holzer	
 		Title:	President	

 	CELGENE SWITZERLAND LLC	
 	 	
 	By:	/s/ Kevin Mello	
 		Name:	Kevin Mello	
 		Title:	Manager	

 	CELGENE EUROPEAN INVESTMENT COMPANY	
 	 	
 	By:	/s/ Kevin Mello	
 		Name:	Kevin Mello	
 		Title:	Manager	

 	CELGENE ALPINE INVESTMENT CO., LLC	
 	 	
 	By:	/s/ Kevin Mello	
 		Name:	Kevin Mello	
 		Title:	Manager